Mild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: A prospective study.

Autor: Garcia-Broncano P; Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, United States. Electronic address: pgarciabroncano@gmail.com., Medrano LM; Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain. Electronic address: luzmedranodios@gmail.com., Berenguer J; Unidad de Enfermedades Infecciosas/VIH; Hospital General Universitario 'Gregorio Marañón', Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain. Electronic address: jbb4@me.com., Brochado-Kith O; Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain. Electronic address: brochado1993@gmail.com., González-García J; Unidad de VIH, Servicio de Medicina Interna, Hospital Universitario 'La Paz', Madrid, Spain. Electronic address: juangonzalezgar@gmail.com., Jiménez-Sousa MÁ; Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain. Electronic address: jimenezsousa@isciii.es., Quereda C; Servicio de Enfermedades Infecciosas, Hospital Universitario Ramón y Cajal, Madrid, Spain. Electronic address: cqueredar.hrc@salud.madrid.org., Sanz J; Servicio de Medicina Interna, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain. Electronic address: jsanz.hupa@salud.madrid.org., Téllez MJ; Servicio de Medicina Interna, Hospital Clínico de San Carlos, Madrid, Spain. Electronic address: mtellez.hcsc@salud.madrid.org., Díaz L; Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain; Unidad de Citometría de Flujo y Sorter, Hospital General Universitario 'Gregorio Marañón', Madrid, Spain. Electronic address: lauradiaz@gmail.com., JIménez JL; Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain; Plataforma de Laboratorio, Hospital General Universitario 'Gregorio Marañón', Madrid, Spain. Electronic address: joseluis.jimenez@salud.madrid.org., Resino S; Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain. Electronic address: sresino@isciii.es.
Jazyk: angličtina
Zdroj: The Journal of infection [J Infect] 2020 Jan; Vol. 80 (1), pp. 99-110. Date of Electronic Publication: 2019 Oct 01.
DOI: 10.1016/j.jinf.2019.09.020
Abstrakt: Objective: There are a lack of consistency among articles in regards to the evolution of peripheral immune biomarkers after HCV therapy. We aimed to detect the most relevant changes in peripheral immune biomarkers among HIV/HCV-coinfected patients who achieved sustained virologic response (SVR) following peg-IFN-α/ribavirin therapy and to evaluate its normalization with respect to an HIV-monoinfected control group.
Methods: We performed a prospective cohort study in 99 HIV/HCV-coinfected patients with samples at baseline (HIV/HCV-b-group) and at week 24 after SVR (HIV/HCV-f-group). We also used a control group of 39 HIV-monoinfected patients (HIV-group) negative for HCV and HBV infections, and who had undetectable HIV viral load and CD4 + >500 cells/mm 3 . Peripheral T cell subsets were assessed by flow cytometry and plasma biomarkers by immunoassays.
Results: HIV/HCV-coinfected patients had higher values of in IL-10, IL-4, IP-10, IL-8, IL-1β, IL-18, IL-6, IFN-γ, IL-12p70, TNF-α, sVCAM-1, sICAM-1, and sTNFR-1 than HIV control subjects, both at the beginning and at the end of follow-up. Moreover, three biomarkers (CD4 + CD38 + , telomere length, and IL-1RA) were normalized in relation to the control group at the end of follow-up (the HIV/HCV-b group had higher values and the HIV/HCV-f group had similar values as the HIV-group). Additionally, LPS, IL-2, and IL-17A levels were higher in the HIV/HCV-f group than the HIV-group (24 weeks after SVR). During the follow-up, HIV/HCV-coinfected patients had a significant decrease by the end of follow-up in CD8 + CD45RA - CD28 + , CD4 + CD38 + , CD4 + CD25 + CD127 -/low , CD4 + CD25 + CD127 -/low CD45RA - , FABP2, LBP, IP-10, sVCAM1. Only CD4 + CD38 + was normalized.
Conclusion: HIV/HCV-patients showed a slight improvement in the overall profile of immune biomarkers after achieving SVR.
(Copyright © 2019. Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: